Identification of high-risk stage II and stage III colorectal cancer by analysis of MMP-21 expression

Journal of Surgical Oncology

Volumn 104, Issue 7, 2011, Pages 787-791

  Wu, Tao ^a   Li, Yi ^a   Liu, Xiaohong ^b   Lu, Jianguo ^a   He, Xianli ^a   Wang, Qing ^a   Li, Jipeng ^c   Du, Xilin ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

colorectal cancer; matrix metalloproteinase 21; prognosis

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 21; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; COLORECTAL CANCER; EPITHELIUM; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80255131295     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21970     Document Type: Article

References (39)

1. Wang J,: Current and future situation of colorectal carcinoma screening. J Dig Surg 2006; 5: 303-305.
2. Wolpin BM, Meyerhardt JA, Mamon HJ, et al.: Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57: 168-185. (Pubitemid 46798625)
3. Center MM, Jemal A, Smith RA, et al.: Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-378.
4. Parsons SL, Watson SA, Brown PD, et al.: Matrix metalloproteinases. Br J Surg 1997; 84: 160-166. (Pubitemid 27073454)
5. Curran S, Murray GI,: Matrix metalloprteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630. (Pubitemid 30616366)
6. Nagase H, Woessner JF, Jr:, Matrix metalloproteinases. J Biol Chem 1999; 30: 21491-21494.
7. Nelson AR, Fingleton B, Rothenberg ML, et al.: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149. (Pubitemid 30123793)
8. Park HI, Ni J, Gerkema FE, et al.: Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000; 275: 20540-20544. (Pubitemid 30457636)
9. Stetler-Stevenson WG,: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 2001; 10: 383-392.
10. Hidalgo M, Eckhardt SG,: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-193. (Pubitemid 32166488)
11. Curran S, Murray GI,: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-308. (Pubitemid 29489213)
12. Stetler-Stevenson WG,: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9: 289-303.
13. Chambers AF, Matrisian LM,: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270. (Pubitemid 27371946)
14. Liotta LA, Stetler-Stevenson WG,: Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99-106.
15. McDonnell S, Navre M, Coffey RJ, Jr, et al.: Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991; 4: 527-533.
16. Pyke C, Ralfkiaer E, Tryggvason K, et al.: Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-365. (Pubitemid 23057447)
17. Yoshimoto M, Itoh F, Yamamoto H, et al.: Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993; 54: 614-618. (Pubitemid 23188192)
18. Zeng ZS, Guillem JG,: Colocalisation of matrix metalloproteinase-9 mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996; 74: 1161-1167. (Pubitemid 26360102)
19. Zeng ZS, Huang Y, Cohen AM, et al.: Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133-3140. (Pubitemid 26408807)
20. Poulsom R, Pignatelli M, Stetler-Stevenson WG, et al.: Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-396.
21. Liabakk NB, Talbot I, Smith RA, et al.: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190-196. (Pubitemid 26010399)
22. Ring P, Johansson K, Höyhtyä M, et al.: Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br J Cancer 1997; 76: 805-811. (Pubitemid 27379751)
23. Oberg A, Höyhtyä M, Tavelin B, et al.: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20: 1085-1091. (Pubitemid 30240680)
24. Sis B, Saǧol O, Küpelioǧlu A, et al.: Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract 2004; 200: 379-387. (Pubitemid 38950421)
25. Pesta M, Topolcan O, Holubec L, Jr, et al.: Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007; 27: 1863-1867. (Pubitemid 46954688)
26. Cho YB, Lee WY, Song SY, et al.: Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 2007; 38: 1603-1610. (Pubitemid 47589089)
27. Hilska M, Roberts PJ, Collan YU, et al.: Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-723. (Pubitemid 47106199)
28. Rhodes A, Jasani B, Barnes DM, et al.: Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-130. (Pubitemid 30075056)
29. Curran S, Dundas SR, Buxton J, et al.: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-8234. (Pubitemid 40053382)
30. Lyall MS, Dundas SR, Curran S, et al.: Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006; 12: 1184-1191. (Pubitemid 43342507)
31. Ahokas K, Lohi J, Lohi H, et al.: Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer. Gene 2002; 301: 31-41. (Pubitemid 35461986)
32. Marchenko GN, Marchenko ND, Strongin AY,: The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J 2003; 372: 503-515. (Pubitemid 36723896)
33. Suomela S, Koljonen V, Skoog T, et al.: Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma. Virchows Arch 2009; 455: 495-503.
34. Boyd S, Virolainen S, Pärssinen J, et al.: MMP-10 (Stromelysin-2) and MMP-21 in human and murine squamous cell cancer. Exp Dermatol 2009; 18: 1044-1052.
35. Germani RM, Civantos FJ, Elgart G, et al.: Molecular markers of micrometastasis in oral cavity carcinomas. Otolaryngol Head Neck Surg 2009; 141: 52-58.
36. Qiu W, Zhou G, Zhai Y, et al.: No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol Biomarkers Prev 2008; 17: 2514-2518.
37. Bister V, Skoog T, Virolainen S, et al.: Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol 2007; 20: 1128-1140. (Pubitemid 47609068)
38. Shagisultanova EI, Novikova IA, Sidorenko YS, et al.: The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res 2004; 24: 199-201. (Pubitemid 38279708)
39. Ahokas K, Lohi J, Illman SA, et al.: Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Lab Invest 2003; 83: 1887-1899. (Pubitemid 38018552)